2014
DOI: 10.1371/journal.pone.0108487
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacologic Inhibition of MLK3 Kinase Activity Blocks the In Vitro Migratory Capacity of Breast Cancer Cells but Has No Effect on Breast Cancer Brain Metastasis in a Mouse Xenograft Model

Abstract: Brain metastasis of breast cancer is an important clinical problem, with few therapeutic options and a poor prognosis. Recent data have implicated mixed lineage kinase 3 (MLK3) in controlling the in vitro migratory capacity of breast cancer cells, as well as the metastasis of MDA-MB-231 breast cancer cells from the mammary fat pad to distant lymph nodes in a mouse xenograft model. We therefore set out to test whether MLK3 plays a role in brain metastasis of breast cancer cells. To address this question, we use… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
5
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 10 publications
(6 citation statements)
references
References 25 publications
1
5
0
Order By: Relevance
“…On the other hand, the mouse model showed a difference of adhesion between the two cancer cell lines where MDA-MB-231 cells interacted in a larger amount compared to MCF-7. This result using the mouse in vitro BBB model is consistent with the results obtained with animal studies [ 29 ]. Hence, associated to in vivo experiments, the mouse model could represent a relevant BBB model to study brain metastases at a cellular and molecular level but is not suitable for human mechanistic studies.…”
Section: Discussionsupporting
confidence: 91%
“…On the other hand, the mouse model showed a difference of adhesion between the two cancer cell lines where MDA-MB-231 cells interacted in a larger amount compared to MCF-7. This result using the mouse in vitro BBB model is consistent with the results obtained with animal studies [ 29 ]. Hence, associated to in vivo experiments, the mouse model could represent a relevant BBB model to study brain metastases at a cellular and molecular level but is not suitable for human mechanistic studies.…”
Section: Discussionsupporting
confidence: 91%
“…C57BL/6J male mice were randomly assigned to eight groups: Sham, TAC, TAC + U-099, Sham + AAV NC , TAC + AAV NC , TAC + AAV MLK3− , TAC + atagomir, and TAC + agomir. TAC + U-099 mice were generated by intraperitoneal (i. p.) injection of URMC-099, an inhibitor of MLK3, has been reported to play an important role in a variety of diseases including anti-inflammatory and cognitive decline 34,37 and as a useful tool to investigate the role of MLK3 in other diseases is common [38][39][40] (10 mg/kg, dissolved in 10% DMSO, 40% PEG300, and 50% saline, every 12 h, MedChemExpress, Shanghai, China) 7 days before TAC surgery. Sham and TAC mice received corresponding isotype i.p.…”
Section: Animalmentioning
confidence: 99%
“…We treated HIV-1 ADA strain-infected (HIV-1 ADA -infected) MDMs with 400 ng/ml URMC-099, followed by subtherapeutic concentrations (1 μM) of nanoformulated ATV (nanoATV) at 1, 3, and 5 days after infection at a multiplicity of 0.1 infectious virions per cell. The concentration of URMC-099 used elicited a maximal therapeutic efficacy that included drug particle retentions, amyloid β clearance, cellular vitality, and robust neuroprotective and antiinflammatory responses (11,(16)(17)(18)(19)(20). As concentrations of nanoATV of 100 μM or greater suppress viral replication, we performed URMC-099 dose-response determinations using subtherapeutic nanoATV concentrations for the measurement of viral growth.…”
Section: Urmc-099 Facilitates Nanoart Activitymentioning
confidence: 99%